cDNA MICROARRAYS EXPERIMENTAL DESIGN AND GENE EXPRESSION ANALYSIS OF GENISTEIN TREATED HUMAN PROSTATE CANCR CELLS PC-3 by SUHAROSCHI, RAMONA et al.
Bulletin USAMV-CN. 63 - 64/2007 
 
 
cDNA MICROARRAYS EXPERIMENTAL DESIGN AND GENE 
EXPRESSION ANALYSIS OF GENISTEIN TREATED HUMAN 
PROSTATE CANCR CELLS PC-3 
 
Suharoschi Ramona, IR Rowland, H Klocker, RL Hancock, RS Pardini, Al.Baba  
 
1Human Nutrition Department. Food Science and Technology. Comparative Oncology Department. 
University of Agricultural Sciences and Veterinary Medicine of Cluj. Romania. 3-5 Manastur. 3400 
Cluj-Napoca. Romania 
2Northern Ireland Centre for Food and Helath (NICHE). School of Biomedical Sciences. University of 
Ulster. Cromore Road. Coleraine. N. Ireland. BT52 1SA. UK 
3Urological Laboratory. Department of Urology. Innsbruck Medical University. Anichstrasse 35. A-
6020 Innsbruck. Austria 
4Cancer Research Laboratory. Biochemistry Department. School of Medicine. College of Agriculture. 
University of Nevada. Reno. MS330. 1664 N Virginia St. 89557. Reno. NV. USA 
 
*Corresponding author; Tel: +40 264 425575. Fax: +40 264 425575. e-mail: laslora@yahoo.com 
 
Key words: PC3. Genistein. cDNA microarrays 
 
Abstract. cDNA microarrays was developed to investigate the relative expression of the corresponding 
total RNA in prostate cancer cell line PC-3 (AR-) treated with therapeutically doses of Genistein 50uM 
compared with untreated PC-3 prostate cancer cells. For generating fluorescently labeled cDNA samples to be 
used in microarray screening we used the SuperScriptTM Indirect cDNA Labeling System (InvitrogenTM). 
Hybridization procedure was performed overnight using a humidified Corning chamber at 450 C in water bath. 
The image analysis was performed using GenePix Pro 41121 and ImaGene and for Data analysis we used 
GeneSight. GeneSpring and MATLAB (MatArray and maanova) software for expression analysis. The  gene 
expression analysis revealed that Genistein at therapeutically and physiologically doses as well caused a 
differential expression of: “6-phosphofructo-2-kinase/fructose-2. 6-biphosphate 3”. “ATPase. Ca++ transporting. 
ubiquitous”. “BTG family. member 2”. “H2A histone family. member L”. “H3 histone. family 3A” "UDP-
Gal:betaGlcNAc beta 1.4- galactosyltransferase. polypeptide 2". "calcium channel. voltage-dependent. L type. 
alpha 1C subunit". "calmodulin 3 (phosphorylase kinase. delta)". "caspase 5. apoptosis-related cysteine 
protease". "chaperonin containing TCP1. subunit 7 (eta)". "general transcription factor IIH. polypeptide 4. 
52kDa". "phosphatidylinositol transfer protein. membrane-associated". "polymerase (RNA) II (DNA directed) 
polypeptide A. 220kDa". "potassium voltage-gated channel. KQT-like subfamily. member 2". "protein tyrosine 
phosphatase. non-receptor type 3". "protein tyrosine phosphatase. non-receptor type 7". "ras homolog gene 
family. member N". "transcription elongation factor B (SIII). polypeptide 1 (15kDa. elongin C)". "transcription 
factor B2. mitochondrial". "tumor necrosis factor. alpha-induced protein 2". Cdc42 guanine nucleotide exchange 
factor (GEF) 9. DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 38 acrosomal vesicle protein 1. protocadherin 
1 (cadherin-like 1). putative nucleolar RNA helicase. regulator of G-protein signaling 3. ubiquitin specific 
protease 11. vesicle-associated membrane protein 2 (synaptobrevin 2). We conclude that Genistein can 
preferentially cause a decrease of some gene involved in apoptosis pathways and an increase in others in human 
prostate cancer PC-3 cell line. We make a bioinformatics analysis for the identified genes involved in apoptosis 




Prostate cancer is the second leading cause of adult male deaths from cancer in the United 
States (Weir et al.. 2003). Prostate cancer is also most predominant in North America and north-
western Europe and less common in Asia. Africa and South America. In Europe the prostate cancer 
incidence depends to some extent on which country you live in. According to the Office of National 
Statistics – UK. prostate cancer is now the most common form of male cancer. This is due to better 
diagnosis based on the Prostate Specific Antigen (PSA) mass screening programs . with an observed 
drop in mortality. e.g. in Austria compatible with freely available PSA testing - the Tyrol programme - 
(Boyle et al. 2001).  
The growth of human prostate tumors is highly responsive to androgen. which resulted in the 
development of hormonal anti-cancer therapies. The generally accepted model is that androgen causes 
increased proliferation of prostate cancer cells and that androgen withdrawal or combined androgen 
blockade (CAB) has the potential to inhibit the growth of prostate cancer (CaP) cells. ultimately 
leading to the induction of apoptosis (Whitcare et al. 2002). However. despite an early favorable 
response to androgen ablation therapy. resistance to hormonal therapies is almost inevitable. resulting 
in regressed tumors invariably relapsing as androgen-independent tumors and metastases (Meyer et al. 
2003. Klocker et al. 1999). The lack of responsiveness to this hormonal therapy led to the 
investigation of new chemotherapeutic agents. Phytoestrogens are currently being considered for use 
in chemoprevention and treatment of prostate cancer.  In recent years there has been great emphasis on 
the consumption of diets rich in fruits and vegetables that reduce the risk of prostate cancer due to 
their high content of flavonoids. These protective effects are mediated at least in part by dietary 
phytoestrogens. Many epidemiological studies have found a direct correlation between a low incidence 
and mortality of prostate cancer in Asian men who consume a traditional diet high in soy products 
(Adlercreutz et al.. 1995; Jacobsen et al. 1998).  
The precise mechanism responsible for the antitumor effect of flavonoids is not yet fully 
understood. It is clear that flavonoids affect various metabolic pathways such as activation of 
glycolytic enzymes or protein synthesis (Middleton and Kandaswami. 1993). They can also promote 
cell cycle arrest in G0/G1 or G2/M phase. depending on their structure and cellular model (Lepley and 
Pelling. 1997; Lepley et al.. 1996). Some flavonoids were shown to be potent inducers of chromatin 
condensation and apoptosis in some cancer cells (Csokay et al.. 1997; Kuo. 1996; Wei et al.. 1994).   
Inhibition of proliferation and/or induction of apoptosis are two mechanisms that we 
hypothesise to be responsible for the prostate cancer cell death induced by isoflavones. The main aim 
of this study was to investigate the genes and proteins modulated by phytoestrogens with a special 
focus on genes and gene products  involved in the regulation of cell cycle and apoptosis and in 
androgen action in the human androgen-insensitive prostate cancer cell line PC-3 (-AR) cells by a 
genomics study. which employ a cDNA microarrays. 
Our preliminary studies have shown that the isoflavones. phytoestrogens from soybean 
(Genistein and Daidzein). exerted a growth inhibitory effect on the prostate cancer (PC-3 and LNCaP) 
cell lines. We aim to investigate this effect further and delineate the underlying molecular mechanism. 
This should allow the identification of molecular markers and therapeutic targets.  
 
MATERIAL AND METHOD 
 
Chemicals. Phytoestrogens were obtained from Sigma-Aldrich (Dorset. UK). Cell culture 
reagents were obtained from Invitrogen (Paisley. UK). 
Cell Culture. PC-3 (-AR) cells were obtained from the American Type Culture Collection - 
ATTC (Manassas. VA) and from the European Collection of Cell Cultures –ECACC (Sailsbury. UK) 
and maintained in Nutrient mixture F-12 (Ham) with L-Glutamine Medium (Invitrogen Corporation-
GIBCO. cat# 21765-029) supplemented with 7% foetal calf serum (FBS). 1% penicillin/streptomycin. 
Cells were cultered as monolayers and maintained at 370C in a 5% CO2 / 95% air humidified 
atmosphere. Prior to experiments. cells were transferred to Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (Ham 1:1) with L-Glutamine without HEPES buffer. without phenol red 
(Invitrogen. cat# 21041-025) medium that was serum and phenol-red free in order to eliminate 
potential oestrogenic compounds. 
In vitro Cell Growth Assay. Cells/well (1.5 – 3 x 104) were cultred in 6-well plates (Corning 




 Fig. 1 Growth Assay Design (count cells after 24. 48. 72 and 96 hours) 6-day and 7-day growth assay. 
 
 
 Cell number was counted daily using a Neubauer hemocytometer chamber (Hausser 
Scientific. Horsham. PA). For this purpose. the culture medium was removed; cells were washed with 
warm PBS. and incubated with 2 ml of trypsin-RDTA (Invitrogen) for 7-10min. After adding another 
2 ml of complete media. we harvested cells in falcon tube and concentrated cells by centrifuge at 
10.000g for 5min. We determined cell viability with Trypan Blue (TB): 50ul TB+ 30ul DPBS + 20ul 
sample (d.f.=5). 10 ul of the solution were placed onto the hemocytometer and we counted cells at 24. 
48. 72 hours. The data were expressed as number of cells/ml and analyzed using GraphPad Prism 3.0.  
cDNA Microarrays analysis. The MIAME (Minimum information about a microaray 
experiment) – toward standards for microarray data are the following: 
1. Experimental Design 
2. Array design (two-channel microarray data; cDNA microarrays from HGMP-RC. Gene_ID-
list) 
3. Sample preparation (samples used. extraction preparation) 
4. Probe labeling 
5. Hybridization (procedures and parameters) 
6. Washing off steps 
7. Data acquisition by fluorescent scanning of the array: Axon 4000a scanner using SOP 
(detection unit: PMT. image acquisition: simultaneous Cy3 and Cy5 acquisition. optical 
system: confocal) and scanning slides with GenePix Pro 41121. 
8. Data analysis using GeneSight. MATLAB (MatArray and Maanova) 
 
1. Experimental Design 
We had been used a common reference design for microarrays. all the direct comparisons are 
made to a reference sample (between treated prostate cancer cells with untreated ones) using the same 
orientation of dye labeling. In this design. dye effects are confounded with treatment effects (Genistein 
10uM and 50uM). The experimental variables in this study are: the doses (Gensitein 10uM and 
50uM). genetic variation or response to a compound/treatment. The general quality related indicators 
such as usage and types of replicates and quality- control steps was technical replicates (the array 
design. and two repeats from the same biological sample).  
2. Array Design (two channel microarray data; cDNA microarrays from HGMP-RC. 
Gene_ID-list) 
The microarrays used in the experiment were customer glass-slide spotted with PCR-amplified 
cDNA clones available from the HGMP-RC (the Human Genome Mapping Project Resource Center. 
UK – Human cDNA Clone Set Array version 2 ~ 5.4k cDNA on 1 slide. product No. 300011 00 
(25-6700-01). CodeLinkTM Activated Slides. Amine Binding Slides (Amersham Biosciences. NJ). 
Each slide is identified by a Barcode. For experiment we used HGMP RC 0107039003 Hs 1-14sc 
ALSBRM123 and HGMP RC 0107039004 Hs 1-14sc ALSBRM123 arrays. Barcode text (date/robot 
ID/slide): 0107039003 and 0107039004; Resource Centre: HGMP RC; Gene set: Hs; Plate number: 1-
14; Arrayer: A; Operator: LSBRM; Run ID: 123.   
Description of Arrays 
Human cDNA Clone Set Array version 2 ~ 5.4k cDNA on 1 slide 
The majority of the clones printed on this array are from the HuGen set. the HGMP Resource 
Centre’s minimally redundant human gene set. 3.360 clones have been sequenced verified in 
collaboration with the Sanger Centre. and re-arrayed. The human cDNA array also contains insert 
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PCR products from an “Angiogenesis set” prepared by the Reproductive Molecular Research Group. 
Dept. of Pathology. University of Cambridge. The 979 clones have been sequence verified by the and 
kindly provided to us for use in this program. This generation 2 array also contains 786 clones from 
the Mammalian Gene collection. This collection. which is produced by the I.M.A.G.E. Consortium. 
seeks to identify and sequence a representative full open reading frame clone for each human gene. 
The clones present on this array are from the IRAK set. 
Using the Amersham Biosciences Lucidea Scorecard. control clones are also present on this 
array. There are 10 housekeeping genes present. 5 negative controls including Bacillus substilis and 
Arabidopsis thaliana genes. 6 dynamic range controls and 4 ratio range controls. The inserts from 
these three gene sets have been amplified using vector-specific primers just flanking the cDNA insert 
and purified using Millipore Multiscreen PCR plates. The purified PCR products have then been re-
arrayed into 384 well plates containing the appropriate printing buffer and spotted onto Corning GAP 
II slides using an Amersham Biosciences Lucidea Array Spotter. Printed arrays contain four meta-
columns and twelve meta-rows. thus there are 48 grids in total (figure 2). Duplicate spots are placed in 
the same relative position in two separate meta-columns i.e. meta-column 2 is a replicate of meta-
column 1 and meta-column 4 is a replicate of meta-column 3. Overall array dimensions are 
approximately: length 53 mm. width 18 mm. There are 15 rows and 16 columns within each grid i.e. 
240 spots. Average spot diameter is 190 um and average distance from spot-to-spot center is 250um. A 















Figure 2. Layout of Human cDNA Clone Set Array version 2 (~4.5k cDNAs) 
 
3. Sample preparation (samples used. extraction preparation) 
RNA extraction. Preparation of the cDNA-labeled Probes. Total RNA was extracted from 
PC-3 prostate cancer cells treated with Genistein 50uM for 72 hours (maximum no. cells = 1 x 107) 
using the RNeasy® Mini Kit (QIAGEN. cat. # 74104)o the manufacturer’s protocol. The quality of the 
RNA was assessed by electrophoresis through running aliquots on agarose gel followed by ethidium 
bromide staining. The amount of RNA and sample purity were determined by measuring the 
absorbance at 260 nm and the 280/260 nm ration. respectively. Only samples with a ratio ≥ 1.8 were 
used.  
4. Probe labeling 
First – strand cDNA was performed using the SuperScript™ Indirect cDNA Labeling System 
for generating fluorescently labeled cDNA to use in microarray screening. (INVITROGEN cat.# 
L1014-01) according to the manufacture’s protocol. Briefly. 18ug of total RNA from both the 
reference sample (PC-3 untreated cells) and the experimental samples (PC-3 Genistein 50uM treated 
cells) were reverse transcribes for 3 h at 420 C using Cyanine 3-dCTP (FluoroLinkTM CyTM 3-dCTP 
PA53021. Amersham Biosciences. Amersham Place Little Chalfont Buckinghamshire. UK) for the 
reference sample and Cyanine 5-dCTP (FluoroLinkTMCyTM 5-dCTP PA55021. Amersham Biosciences 
Amersham Place Little Chalfont Buckinghamshire. UK) for the experimental samples. Reference and 
experimental cDNA probes were mixed in equal amounts. The probe mix was filtered through an 
CyScribe GFX Purification Kit  (product code: 27-9606-01. Amersham Biosciencs. Amersham Place 
Little Chalfont Buckinghamshire. UK) to eliminate the unincorporated nucleotides. After two washes 
with wash buffer. the labeled cDNA mixture was filter concentrated to a final volume of 50ul. The 
total Cy dye incorporation from the purified sample was determined with spectrophotometer reading 
for Cy5 detected at 650 nm and Cy3 detected at 550 nm (P.S. Yan et al. Mehods 27 (2002) 162-169. 
To calculate the picomoles of dye incorporated. the following two equations were used: 
A550 x (total volume of target)/0.15 = pmol of Cy3 dye incorporated. 
A650 x (total volume of target)/0.25 = pmol of Cy5 dye incorporated. 
5. Microarray hybridization (procedures and parameters) 
Before hybridization procedure a pre - hybridization step was performed. The slides were 
placed in coplin jar containing pre-hybridization buffer (a solution consisting of 5xSSC. 0.1%SDS and 
1% BSA for 45 min at 450C). After that the slides were washed by dipping in filtered MilliQ water 5 
times and in Isopropanol 5 times and left on tissue paper to air-dry for ~ 10min. After thorough 
mixing. 25ul of hybridization buffer (containing 0.25 M sodium phosphate. 4.5% SDS. 1 mM EDTA. 
and 1xSSC) was added to the samples. and left to stand for 10 min at room temperature.  We mixed 
together 15ul of Cy5-dCTP labeled probe (remainder placed at -200C). 15ul of Cy3labelled probe 
(remainder placed at -200C). 1.0 ul COT-1 DNA (10ug/ml) (Invitrogen). 1.0 ul (10 ug) of Poly-A 
(Amersham Biosciences).  denaturated at 950C for 5 min and cooled on ice for 10 min. The samples 
were placed carefully onto microarrays and placed 24 x 60-mm coverslip on top. The microarray was 
left in humidified Corning chamber overnight at 450C in water bath to carry out the hybridization.  
6. Washing off steps 
After hybridization. the coverslip was removed gently by inverting in 2 x SSC containing 0.2 % 
SDS (3ml of 20xSSC in 30ml dH2O plus 600ul of 10% SDS). Further on. the slides were washed 
sequentially in a series of solutions with increasing stringency: in 2 x SSC containing 0.1% SDS 
(2x5min). in 1 x SSC (2x5min). and in 0.1 x SSC (2x5min). Finally. the slides were dipped in filtered 
MilliQ water for 5 times and in filtered Isopropanol for 5 times. After washing steps the slide was 
centrifuged at 2.000 rpm for 2 min. 
Two separate hybridizations were performed for cell lines using PC-3 untreated cells as reference.  
7. Data Filtering. Normaliaztion and Statistical Analysis 
Data acquisition by fluorescent scanning of the array using an Axon 4000a scanner  (detection 
unit: PMT. image acquisition: simultaneous Cy3 and Cy5 acquisition. optical system: confocal) 
and scanning slides with GenePix Pro 41121 software. 
Immediately after the washing. slides were scanned with an GenePix 4000A scanner (Axon) 
fluorescence laser-scanning instrument with a high-resolution “DATA-SCAN” (Axon Istruments. 
Foster City. CA). The settings of the scanner photomultiplier tubes for the Cy5 (650 nm) and the Cy3 
(550 nm) channels were established during the preliminary fast scan to achieve a balance between the 
two fluorescence intensities. A final high-resolution scan was performed based on these scanning 
parameters.  
 
Purpose: post-hybridization with fluorescent targets. we scan the slides with lasers that excite 
the Cy3 and Cy5 dyes. The scanned images are collected using the GenePix Pro3 scanning. imaging 
and quantitation software and the GenePix 4000a scanner. After the images are aquired and stored on 
the server as multiimage tiff files. we use the software to overlay the GenePix Array List (GAL file) to 
allow quantitation of the fluorescent intensities of the features and association of features with the 
gene identifies and descriptions. Balancing the PMT (photomultiplier tube) settings for each of the 
lasers over many features. and preferably the whole slide. is critical to balance out the differences in 
the specific fluorescent activities of the two targets (GenePix Po Microarray Acquisition and Analysis 
Software). 
8. Image analysis using GenePix Pro 41121 and ImaGene 
The readings from the quantitative scanning were analyzed by the BioDiscovery ImaGene 5.6 
Image Processing Software and BioDiscovery GeneSight 4 Data Mining Software (local service from 
MWG Biotech). Image analysis and calculation of average foreground signal adjusted for local 
channel-specific background were performed using GenePix Pro 41121 software and ImaGene 5.0 
software. Each spot was defined by the positioning of a grid of circles over the array image. The 
average pixel intensity within each circle was determined by subtracting this background from its 
corresponding median average intensity. After gridding. each dot on the 24-bit ratio image was 
visually inspected and. if necessary. unsatisfactory dots were manually flagged. These data were 
exported into an Excel spreadsheet as a GenePix results (*.gpr) file of the raw data (F635 median - B 635 
median. F532 median - B 532 median and was used for subsequent data analysis as described.  
9. Data analysis using GeneSight. MATLAB (MatArray and Maanova) 
The gene expression levels of samples were normalized and analyzed by using GeneSight 4. 
MATLAB (MatArray and Maanova) and Data Mining Tool software from BioDiscovery (local service 
from MWG Biotech). The absolute call (present. marginal. absent) and the average difference of total 
genes: 11520 from which 4486 active genes ( ~5.4k cDNAs) in a sample. and the absolute call 
difference. fold change. average difference of gene expression between the two samples were 
normalized and identified using these software. The data transformation sequence used were the 
following: a) Background correction (Local Background Correction); b) omit flag type (Omit Multiple 
Flagged Spots: 1 – bad); c) floor: entered value for the floor: 20.0); d) normalization (use all genes to 
normalize with); e) Normalizations used: subtract percentile; f) combine replicates. Then we 
performed the confidence analysis. To visualized the results were used histogram analysis. ScatterPlot 
analysis Tool and BoxPlot. We selected genes which were twofold up- and down- differentially 
expressed. The average-linkage hierarchical clustering of the data was applied by using the Cluster 
(Eisen et al. Stanford) and the results were displayed by using TreeView (Eisen et al. Stanford) and 
MATLAB (MatArray and Maanova). 
10. Statistical analysis of cell culture study 
A Prism 3.0 software package (GraphPad Software. Inc.. CA. USA)was utilized for statistical 
analysis of cell culture study. The results were analyzed by t-test. Observations were claimed to be 
significant different when P< 0.05 was achieved. To derive the IC50 values for growth inhibition. a 
nonlinear approximation model by the least square methods based on a competition curve using one 
component was applied (GraphPadPrism. GraphPad. USA). For each variable at least 3 independent 
experiments were carried out. Data are given as the mean ± SEM. 
 
RESULTS AND DISCUSSIONS 
 
Cell Growth inhibition of prostate cancer PC-3 cells (-AR) by Genistein treatment. The 
growth-inhibitory effect of Genistein is shown in the Fig. 3. was determined in monolayer treated PC-
3 human prostate cancer cells after 24. 48 and 72 h of exposure to concentrations of 50 to 250 uM 
Genistein. Concentrations that caused 50% inhibition of cell proliferation when compared to controls 
was IC50  approximately 50 uM. The results demonstrated the growth inhibitory effect of Genistein on 
the PC-3 treated cells. These results are consistently with our previous data. This inhibition of cell 
proliferation could be due to altered regulation of gene expression patterns by Genistein.  In PC-3 cells 
 Genistein induce a growth-inhibitory effect in a dose-dependent manner. The Pvalue was 
determined by student t-test. at 95% confidence intervals.  
 
 





























Fig.3 The Growth - inhibitory effect of Genistein on PC-3 prostate cancer cells (AR-) exposed to physiologically 
and therapeutically doses (1 and 35 uM) Genistein. 
 
 
Gene expression analysis. To screen the effect of Genistein on prostate cancer cells PC-3 
(androgen independent). the gene expression profiles of PC-3 cells treated with Genistein were 
assessed using the cDNA microarray technique. We investigate the genes modulated by Genistein with 
a special focus on genes involved in apoptosis. Two independent experiments demonstrated that 
approximately 102 genes were up- or down-regulated more than twofold after Genistein treatment. 
Subtract by percentile normalization were applied to analyze the data from the two independent 
microarrays experiment performed as follows: a) background orrection parameters (local background 
correction; omit flag type 1=bad; floor = 20.0; log = 2 (base) and shift value = 0.00; normalization 
parameters; use all genes to normalize with; normalization used: subtract by percentile; difference – 
combine; combine replicates); b) Apply Data Preparation; c) Confidence analysis (tails lower bound: -
1; Left selected Genes = 5 and upper bound: +1; Right Selected Genes = 97).  
The gene expression profiles of PC3 cells treated with genistein were assessed using cDNA 
microarray. Two independent experiments showed the expression of 832 genes at the mRNA level 
with more than a twofold change after genistein treatment. Among these genes. 774 were down-
regulated and 58 were up-regulated by genistein. Cluster analysis showed nine different types of 
expression alternations (Fig. 2). Cluster 1 and cluster 9 included the genes showing typical gradual 
decreases and increases at the level of expression. All alternations of gene expression in clusters 1 and 
9 were significant (P < 0.05). The altered expressions of most genes occurred as early as after 6 h of 
genistein treatment and were significantly greater with longer treatment.  
These genes were also subjected to cluster analysis according to location and cellular 
components. The genes showing altered expression were located mostly on chromosomes 1. 19. 17. 2. 
6 and 11. and were mainly responsible for the transcription and translation of components of the 
nucleus and integral plasma membrane proteins. After clustering based on biological function. we 
found that genistein down-regulated genes that are involved mainly in signal transduction. 
oncogenesis. cell proliferation. protein phosphorylation and transcription. On the other hand. genistein 
up-regulated genes that are related mainly to signal transduction. protein dephosphorylation. heat 




Fig. 4. Cluster analysis of genes showing alternations in mRNA expression after genistein treatment. 
Nine different types of expression alternation were shown. Cluster 1 and cluster 9 included the genes showing 
gradual decreases and increases at the level of expression typical  
When classified by molecular function. genistein down-regulated genes responsible for RNA 
binding. transcription factors. protein kinases including NF- B-inducing kinase and MAP kinase 
kinase. apoptosis inhibitor and collagenase.It up-regulated tumor suppressors. proteinase inhibitors 
and CDK inhibitors. Genistein also affected specific genes critically involved in the regulation of cell 
cycle. apoptosis. angiogenesis. invasion. metastasis and cell signaling pathways.  
CONCLUSIONS 
 In this study. we utilized the high throughput gene chip. which contains 12.558 known genes. 
to determine the alternation of gene expression profiles of PC3 prostate cancer cells exposed to 
genistein. Our results from cDNA microarray provided a genome-wide analysis of the cellular 
response to genistein treatment. Cellular responses to any antiproliferative agents involve 
modulations of complex pathways that ultimately determine whether a cell survives or dies. 
Cellular and molecular responses of PC3 cells to genistein are complex and are likely to be 
mediated by a variety of regulatory pathways. We found that the molecular response to 
genistein in PC3 prostate cancer cells involved inhibition or induction of genes that are related 
to biochemical. biological and regulatory processes in the cells. These genes have specific 
functions in signal transduction. protein phosphorylation and dephosphorylation. cell 
proliferation and cell cycle control. transcriptional and translational regulation. protein 
degradation and cellular metabolism. They also control cell growth. apoptosis. oncogenesis. 
angiogenesis. invasion and metastasis. These results demonstrated that genistein regulates 
important genes critically involved in cell survival. physiologic behavior and cancer 
progression and may therefore be responsible for inhibiting the progression of prostate cancers. 
The alternations in the expression of these genes were observed at 6 h after genistein 
treatment. and continued to increase for 36 or 72 h. exhibiting time dependency. For example. 
the expression of urokinase plasminogen activator receptor (uPAR). protease M and bone-
derived growth factor (BPGF) declined progressively until 72 h. whereas the expression of 
lamin B receptor. elafin. and vimentin increased progressively. The inhibition of cyclin B 
expression was relatively lower after 6 h of genistein treatment. and maximum inhibition 
occurred after 36–72 h. These results are consistent with the degree of cell growth inhibition as 
documented by 45 and 69.6% inhibition after 48 and 72 h of genistein treatment. respectively. 
These results suggest that genistein may modulate the expression of first-response genes at an 
earlier stage (6 h). and in turn. alter the expression of intracellular second messenger 
molecules. resulting in inhibition of PC3 prostate cancer cell growth and progression. The 
genes showing altered expression by genistein treatment reside mainly on chromosomes 17 
and 19 where many critical genes for cell survival are located. and are mainly responsible for 
the transcription of nuclear and plasma membrane components. suggesting that genistein 
regulates the expression of important genes in cellular signaling.  
 When we categorized the genes showing alternations after genistein treatment according to 
their known function. we found that genistein affected the expression of several genes that are 
involved in tumor invasion and angiogenesis. Among these genes. type IV collagenase (MMP-
9). urokinase plasminogen activator (uPA) and its receptor (uPAR). protease M. protease 
activated receptors (PAR-2). connective tissue growth factor and connective tissue activation 
peptide are very important genes in tumor cell invasion and metastasis (19  –23  ). It has been 
reported that the cancer cells with higher levels of MMP-9. uPA or uPAR tend to invade 
surrounding tissues and subsequently migrate to blood vessels. thereby developing cancer cell 
metastasis (19  .20  ). Connective tissue growth factor and connective tissue activation 
peptide promote the synthesis of the extracellular matrix and rebuild the structure of the 
extracellular matrix. inhibiting invasion and metastasis of cancer (23  ). Vascular endothelial 
growth factor (VEGF). VEGF 165 receptor/neuropilin. transforming growth factor (TGF)-ß. 
thrombospondin (TSP). bone-derived growth factor (BPGF). and lysophosphatidic acid (LPA) 
play important roles in angiogenesis (24  –29  ). Genistein down-regulated the expressions of 
MMP-9. uPA. uPAR. protease M. PAR-2. VEGF. VEGFR. TGF-ß. BPGF. LPA. and TSP. and 
up-regulated the expressions of connective tissue growth factor and connective tissue 
activation peptide. suggesting that it may inhibit angiogenesis. invasion and metastasis of PC3 
prostate cancer cells.  
 From the gene expression profiles of PC3 cells exposed to genistein. we found that this 
compound inhibited the expression of seven genes (cyclin B. cyclin A. cdc25A. survivin. 
TGF-ß. ki67. pescadillo) that are involved in the regulation of the cell cycle and apoptosis. 
Four genes (p57KIP2. cyclin G2. growth arrest and DNA-damage-inducible protein. elafin) 
related to the control of cell growth were up-regulated. Cyclin B. cyclinA and cdc25A are cell 
cycle promoters. whereas p57KIP2 and cyclin G2 inhibit cell cycle progression. The inhibition 
of cyclin B expression shown by cDNA microarray is consistent with our earlier results 
showing the down-regulation of cyclin B in genistein-treated prostate cancer cells. Survivin is 
an important inhibitor of apoptosis. Pescadillo and ki67 promote cell growth. whereas growth 
arrest and DNA damage-inducible protein and elafin inhibit cell proliferation. Our results 
suggest that genistein may inhibit cell growth through regulation of the expression of these 
important genes related to cell proliferation. We also observed altered expression of genes 
encoding kinases including NF- B-inducing kinase (NIK) and MAP kinase kinase. 
differentiation factors. growth factors and transcription factors. suggesting that genistein 
inhibits the cell growth via mediation of cell signal transduction pathways. These results also 
provide mechanistic information in support of our previous observation that the inactivation of 
NF- B may be due to the inactivation of NIK.  
 In summary. we have analyzed the gene expression profiles of PC3 prostate cancer cells 
exposed to genistein. Genistein altered the expressions of many genes that are related to the 
control of cell cycle. apoptosis. cell signaling transduction. angiogenesis. tumor cell invasion 
and metastasis. suggesting pleiotropic effects of this compound. The gene expression profiles 
revealed novel molecular mechanism(s) by which genistein exerts its inhibitory effects on 
prostate cancer cells. Genistein-induced regulation of these genes may be exploited for 
devising mechanism-based chemopreventive or therapeutic strategies for prostate cancer. 
However. further in-depth studies are required to investigate the effects of genistein on the 
regulation of important cellular molecules at the protein levels to examine the effects of 
genistein with cellular functions. 
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